

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Oxford Sciences Innovation plc</u> (Last) (First) (Middle) <u>46 WOODSTOCK ROAD</u> (Street) <u>OXFORD X0 OX2 6HT</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Vaccitech plc [VACC]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/04/2021</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares ⁽¹⁾	05/04/2021		C		4,832,142	A	(3)	4,832,142	D	
Ordinary Shares ⁽¹⁾	05/04/2021		C		1,704,444	A	(3)	6,536,586	D	
Ordinary Shares ⁽¹⁾	05/04/2021		C		1,661,184	A	(3)	8,197,770	D	
American Depositary Shares ⁽²⁾	05/04/2021		P		600,000	A	\$17	8,797,770	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Ordinary Shares	(3)	05/04/2021		C		4,832,142 ⁽⁴⁾		(3)	(3)	Ordinary Shares	4,832,142 ⁽⁴⁾	(3)	0	D	
Series A redeemable convertible preferred shares	(3)	05/04/2021		C		1,704,444 ⁽⁴⁾		(3)	(3)	Ordinary Shares	1,704,444 ⁽⁴⁾	(3)	0	D	
Series B preferred shares	(3)	05/04/2021		C		1,661,184 ⁽⁴⁾		(3)	(3)	Ordinary Shares	1,661,184 ⁽⁴⁾	(3)	0	D	

Explanation of Responses:

- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- Each American Depositary Share represents one ordinary share.
- Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing of Vaccitech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date.
- The number of shares reported reflects the conversion set out in Footnote (3).

Kate O'Brien, for and on behalf of Oxford Science Innovation plc 05/06/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.